Company Overview and News

Tambun Indah likely to gain from potential revised lending policies

2018-08-24 theedgemarkets
Tambun Indah Land Bhd (Aug 23, 98 sen) Upgrade to buy with a higher target price of RM1.13: Tambun Indah Land Bhd’s second financial quarter ended June 30, 2018 (2QFY18) earnings beat our expectations but met the consensus.

Tambun Indah upgraded to buy at Maybank

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): Maybank Kim Eng analyst Wong Wei Sum upgraded the recommendation on Tambun Indah Land Bhd to buy from hold.

Tambun Indah 2Q net profit down 23% on fewer on-going projects

2018-08-21 theedgemarkets
KUALA LUMPUR (Aug 21): Tambun Indah Land Bhd saw its net profit fall 23.3% in the second quarter ended June 30, 2018 (2QFY18) to RM15.08 million from RM19.66 million a year ago, mainly due to fewer on-going projects as the Penang-based property developer adopts a cautious approach given the overall soft market condition.
5191 BSMAF 1818

Tambun Indah’s 2Q-3Q margins expected to improve

2018-07-18 theedgemarkets
Tambun Indah Land Bhd (July 17, 90.5 sen) Hold with an unchanged target price of 91 sen: Tambun Indah Land Bhd’s sales and margins are expected to pick up in the coming quarters on the zero-rating of the goods and services tax (GST) between June and August 2018 and better buying sentiment post-14th general election (GE14) as well as the ongoing marketing campaign.

Stock With Momentum: Tambun Indah Land Bhd

2018-07-18 theedgemarkets
Tambun Indah Land Bhd (+ve) TRADING in the shares of Tambun Indah Land Bhd (fundamental: 2.55/3, valuation: 2.40/3) triggered our proprietary momentum algorithm yesterday for the second time this year.

Ewein, Handal, Opcom, Tambun, Menang

2018-07-17 theedgemarkets
KUALA LUMPUR (July 17): highlighted five stocks with momentum at Bursa Malaysia’s afternoon market close today. Four had positive momentum while
5191 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...